Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Azheimer's disease

Journal of the American Geriatrics Society

Volumn 45, Issue 10, 1997, Pages 1228-1231

  Arai, Hiroyuki ^a   Terajima, Masanori ^a   Miura, Masakazu ^b   Higuchi, Susumu ^c   Muramatsu, Taro ^c   Matsushita, Sachio ^c   Machida, Nobuo ^b   Nakagawa, Takuma ^a   Lee, Virginia M Y ^d   Trojanowski, John Q ^d   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitubishi Kagaku Bioclinical Lab's Inc   (Japan)

^c KURIHAMA NATIONAL HOSPITAL   (Japan)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; TAU PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; DISEASE COURSE; FEMALE; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE CELL DEGENERATION; RISK ASSESSMENT;

EID: 0030883782     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1997.tb03775.x     Document Type: Article

References (25)

1. Trojanowski JQ, Clark CM, Schmidt ML et al. Implications of tau-rich neurofibrillary lesions for the pathobiology and diagnosis of Alzheimer's disease. In: Appel S, ed., Current Neurology, Vol 16. St. Louis: Mosby Year Book, 1996, pp 93-113.
2. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991;251:675-678.
3. Goedert M. Tau protein and neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993;16:460-465.
4. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995;186:189-191.
5. Vigo-Pelfrey C, Seubert P, Barbour R et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-793.
6. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
7. Arai H, Terajima M, Miura M et al. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652.
8. Terajima M, Arai H, Itabashi S et al. Elevated cerebrospinal fluid tau levels: Implications for the early diagnosis of Alzheimer's disease. J Am Geriatr Soc 1996;44:1012-1013.
9. 1-antichymotrypsin polymorphism. Nat Genet 1995;10:486-488.
10. Wragg M, Hutton M, Talbot C, and the Alzheimer's disease collaborative group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet 1996;347:509-512.
11. 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. J Neural Transm 1996;103:1205-1210.
12. Higuchi S, Muramatsu T, Matsushita S et al. Presenilin-1 polymorphism and Alzheimer's disease. Lancet 1996;34:1185-1187.
13. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
14. Vandermeeren M., Mercken M, Vanmechelen E et al. Detection of tT proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
15. Wenham PR, Price WH, Bluindell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.
16. Arai H, Higuchi S, Muramatsu T et al. Lack of association of apolipoprotein E ∈4 allele with progressive supranuclear palsy. Neurodegeneration (letter) 1996;5:194-195.
17. Sherrington R, Rogaeve EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760.
18. Levy-Lahad E, Wasco W, Poorkaj P et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995;269:973-977.
19. Higuchi S, Matsushita S, Hasegawa Y et al. S182 and STM2 missense mutations in sporadic Alzheimer's disease. Am J Med Genet 1996;67:429.
20. Nacmias B, Tedde A, Latorraca S et al. Apolipoprotein E and A1-Antichymotrypsin polymorphism in Alzheimer's disease. Ann Neurol 1996;40:678-680.
21. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
22. Bao F, Arai H, Matsushita S et al. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Neuroreport 1996;7:1733-1739.
23. Kovacs DM, Fausett HJ, Page KJ et al. Alzheimer-associated presenilin 1 and 2: Neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1996;2:224-229.
24. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988;52:487-501.
25. Blomberg M, Jensen M, Basun H et al. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer's disease with Apolipoprotein E allele ∈4 during 14 months follow-up. Neurosci Lett 1996;214:163-166.